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Hydroxyproline	levels	trend	lower	in	mucolytic	treated	mice	
	
	
Figure	3.22:	No	significant	difference	in	hydroxyproline	(HP)	exists	between	treatment	groups,	
though	there	is	a	trend	toward	more	HP	in	vehicle	exposed	mice.		
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Second	harmonic	generation	images	of	aerosol	treated	SPC	Tg+	mice	
	
	
	
Figure	3.23:	Second	harmonic	generation	imaging	shows	collagen	signal	in	red	and	lung	
autofluorescence	in	green.		
	
	
Second	harmonic	generation	quantification	demonstrates	less	collagen	in	mucolytic	
treated	SPC	Tg+	mice	
	
Figure	3.24:	Quantification	of	the	collagen	signal	demonstrates	a	significant	difference	between	
vehicle	and	mucolytic	treated	mice.	P	value	for	a	mixed	effects	model	assessed	by	a	likelihood	
ANOVA.		
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CHAPTER	IV	
DISCUSSION	
Importance	of	findings	
	 This	study	demonstrates	that	expression	and	concentration	of	MUC5B	directly	relates	to	
the	severity	of	bleomycin	induced	murine	fibrosis.	With	rs35705950	known	to	affect	MUC5B	
expression,	this	work	provides	the	first	and	only	functional	evidence	that	a	common	genetic	
variant	can	contribute	to	pulmonary	fibrosis.	Additionally,	this	investigation	indicates	a	key	role	
for	the	distal	airway	in	fibrotic	development,	shifting	the	pathophysiologic	paradigm	away	from	
a	sole	focus	on	the	alveoli.	
Previous	research	connected	rare	mutations	to	idiopathic	pulmonary	fibrosis,	isolating	
changes	in	surfactant	proteins	and	telomerase	components	that	accounted	for	small	
percentages	of	familial	cases.	For	example,	a	2015	Nature	Genetics	paper	identified	two	genes	
involved	in	telomere	length	that	explained	only	7%	of	familial	pulmonary	fibrosis	cases	[228].	
In	contrast,	nearly	all	idiopathic	pulmonary	fibrosis	patients	exhibit	an	increase	in	MUC5B	
expression	[149]	and	a	significant	association	between	rs35705950	exists	for	both	familial	and	
sporadic	disease	[229].	Also,	while	the	association	between	telomere	length	and	IPF	has	been	
replicated	multiple	times	[230],	mice	deficient	in	TERT	or	TERC	do	not	develop	enhanced	
fibrosis	following	bleomycin	[231].	In	comparison,	the	results	herein	not	only	establish	the	
relationship	between	Muc5b	expression	and	fibrosis,	they	also	describe	a	functional	model	for	
further	investigation	of	causative	factors	in	fibrotic	development.		
This	model,	involving	repetitive	injury	in	Muc5b	overexpressing	mice,	places	emphasis	
on	the	distal	airway	as	a	site	for	disease	initiation.	Many	early	hypotheses	in	IPF	centered	on	the	
alveolus,	considering	only	the	destruction	of	type	I	and	type	II	alveolar	cells.	The	discovery	that	
airway	mucin	expression	is	associated	with	disease	challenged	that	system.	Recent	evidence	for	
varying	cilium	gene	expression	in	subtypes	of	IPF	[232]	and	the	association	of	PLUNC,	a	
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bronchial	cell	gene,	with	progression	of	IPF	[233]	support	the	emerging	idea	that	the	airway	
plays	a	critical	role	in	pulmonary	fibrosis.	The	findings	of	this	thesis,	particularly	in	Scgb1a1	
Tg+	mice,	firmly	establish	the	contribution	of	airway	epithelium,	going	beyond	association	
studies	to	in	vivo	validation	through	direct	experimentation.		
The	demonstration	that	a	mucolytic	agent	can	improve	outcomes	following	bleomycin	
exposure	both	validates	the	key	role	of	MUC5B	and	offers	a	promising	new	avenue	for	
treatment.	Initially,	therapy	in	IPF	utilized	anti-inflammatory	medications	including	prednisone	
and	azathioprine,	but	these	proved	ineffective	and	potentially	harmful	[234].	The	current	
standard	of	care	involves	the	anti-fibrotic	agent	pirfenidone,	which	works	on	an	as-yet	
unknown	target	[235],	and	the	growth	factor	receptor	inhibitor	nintedanib,	which	affects	an	
undefined	number	of	potentially	pro-	and	anti-fibrotic	pathways	[236].	A	mucolytic	drug	would	
act	on	an	entirely	different	mechanism,	complementing	the	existing	agents.	With	so	few	options	
available	for	treatment,	and	such	a	bleak	prognosis,	this	work	addresses	a	current	need	for	new	
compounds	combating	IPF.		
Limitations	and	future	directions	
	 The	statistician	George	Box	wrote,	“Essentially,	all	models	are	wrong.	But	some	are	
useful.”	This	aphorism	applies	to	mouse	work	just	as	much	as	ideal	gases,	so	there	are	several	
limitations	of	this	study.	First,	as	mentioned	in	the	Introduction,	bleomycin	in	mice	does	not	
reproduce	many	of	the	features	of	human	idiopathic	pulmonary	fibrosis.	In	fact,	no	mouse	
exposures	completely	recapitulate	IPF,	though	some	characteristics	can	be	induced	through	
different	agents.	For	instance,	structures	similar	to	microscopic	honeycombing	can	form	
following	mouse	infection	with	H1N1	influenza	[237],	suggesting	that	flu	may	be	a	better	choice	
for	study	of	cyst	formation.	Mice	also	fail	to	replicate	the	anatomy	of	humans,	lacking	
respiratory	bronchioles.	An	alternative	animal	model	would	prove	useful	in	clarifying	the	
precise	contribution	of	these	distal	structures.	Ferrets	or	pigs,	both	of	which	have	been	
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successfully	used	to	model	cystic	fibrosis	when	mice	failed	[238],	would	be	excellent	choices	
setting	aside	the	substantial	burden	associated	with	animal	husbandry.		
	 The	data	presented	regarding	ER	stress	suggest	an	association	but	do	not	offer	
definitive	proof	as	a	causative	mechanism	in	fibrosis.	The	input	of	whole	lung	homogenate	for	
gene	expression	work	by	qPCR	and	microarray	severely	limited	interpretation	of	the	results.	
Future	studies	would	benefit	from	the	use	of	single	cell	RNA	sequencing	to	isolate	the	gene	
expression	profile	of	secretory	cells	specifically.	In	addition,	quantification	of	the	apoptotic	
signal	in	Scgb1a1	Tg+	lung	tissue	would	increase	the	reliability	of	the	TUNEL	results.		
	 A	potential	case	against	MUC5B’s	contribution	to	ER	stress	and	IPF	could	be	made	by	
arguing	that	overexpression	of	any	protein,	not	just	MUC5B,	can	induce	ER	stress.	For	example,	
the	replication	of	herpesviruses	triggers	the	unfolded	protein	response	[126],	and	in	the	lungs	
of	IPF	patients,	herpesvirus	proteins	co-localize	with	markers	of	ER	stress[239].	This	provides	
further	evidence	that	ER	stress	may	predispose	to	IPF,	suggesting	that	activation	of	the	
unfolded	protein	response	may	be	a	common	step	in	the	development	of	disease.	Multiple	
agents	could	lead	to	this	shared	point	of	sustained	ER	stress,	including	chronic	herpesvirus	
infection,	smoking	[240],	and	MUC5B	overexpression.	The	high	odds	ratio	(21.8)	conferred	by	
the	variant	at	rs35705950	[149]	and	the	differential	expression	of	MUC5B	by	genotype	in	the	
distal	lung	[156]	support	the	contribution	of	MUC5B	to	IPF.	Thus	while	overexpression	of	
potentially	any	protein	could	lead	to	ER	stress,	the	association	with	the	promoter	variant	points	
specifically	to	MUC5B.		
	 To	extend	this	mouse	work	supporting	an	association	between	ER	stress	and	MUC5B	
overexpression,	assessment	of	human	tissues	should	be	undertaken.	ER	stress	has	already	been	
found	in	IPF	patient	lung	tissue	[133],	but	no	studies	yet	have	attempted	to	stratify	ER	stress	
makers	by	MUC5B	genotype.	Based	on	this	study,	one	would	speculate	that	increasing	copies	of	
the	variant	at	rs35705950	would	associate	with	greater	evidence	of	ER	stress,	particularly	in	
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the	airways.	A	potential	difficulty	of	this	human	lung	assessment	would	be	due	to	the	increase	
in	MUC5B	gene	expression	observed	in	IPF	patients	regardless	of	genotype.	Aging	itself	
compromises	the	ability	of	the	ER	to	maintain	proteostasis	[241],	potentially	exacerbating	the	
effect	of	even	a	small	increase	in	MUC5B	synthesis.	Also,	examinations	of	lung	tissue	from	
patients	undergoing	transplant	restricts	study	to	end-stage	disease,	making	elucidation	of	
inciting	factors	difficult.		
	 The	contribution	of	MUC5B	producing	cells	to	regeneration	could	be	better	examined	
using	lineage	tracing	in	the	mouse	lung	following	injury.	Lineage	tracing	in	mice	wild	type	for	
MUC5B	has	already	demonstrated	the	importance	of	SCGB1A1+	cells	to	repair	[206],	and	
replicating	these	studies	in	the	Scgb1a1	Tg+	mice	would	illustrate	the	effect	of	Muc5b	
overexpression.	If	Muc5b	overexpression	impairs	the	regenerative	ability	of	SCGB1A1+	cells,	
then	lineage	tracing	should	reveal	fewer	and/or	more	poorly	differentiated	daughter	cells	
following	bleomycin	treatment.	This	finding	would	support	the	idea	that	the	IPF	lung	exhibits	
accelerated	senescence	of	progenitor	cells	[242],	adding	MUC5B	overexpression	to	telomerase	
dysfunction	as	a	possible	cause	of	this	premature	aging.		
Ideally,	an	intervention	reducing	ER	stress	should	also	reduce	lung	fibrosis.	
Phenylbutyric	acid	(PBA)	inhibits	ER	stress	by	acting	as	a	chemical	chaperone,	and	has	been	
approved	by	the	Food	and	Drug	Administration	for	treatment	of	urea	cycle	disorders.	A	recent	
study	suggested	that	daily	PBA	injection	mitigates	fibrosis	following	bleomycin	[243],	but	began	
the	injection	regimen	prior	to	bleomycin	exposure,	suggesting	prevention	of	fibrosis	rather	than	
treatment.	Since	PBA	is	known	to	reduce	lung	inflammation	following	lipopolysaccharide	
exposure	[244],	the	reduction	in	fibrosis	with	PBA	treatment	could	be	due	to	an	anti-
inflammatory	effect	rather	than	an	anti-fibrotic	effect.	Similarly,	an	experiment	with	another	ER	
stress	inhibitor,	tauroursodeoxycholic	acid,	demonstrated	a	decrease	in	inflammation	and	
fibrosis	following	bleomycin	exposure	[245],	again	possibly	showing	prevention	rather	than	
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treatment.	Additional	studies	with	different	treatment	regimens	will	be	necessary	to	determine	
how	ER	stress	inhibition	may	influence	fibrosis	specifically,	instead	of	inflammation.	Using	the	
Muc5b	transgenic	mouse	lines	in	these	studies	would	help	clarify	the	contribution	of	MUC5B	
overexpression	to	ER	stress	and	help	explore	the	possibility	for	intervention	based	on	this	
potential	cell	autonomous	mechanism.		
	 Treatment	focused	on	a	non-cell	autonomous	mechanism	occurred	as	part	of	this	work,	
with	a	mucolytic	compound	exhibiting	ability	to	mitigate	fibrosis.	The	mucolytic	findings	can	be	
strengthened	by	demonstrating	that	the	test	compound	corrects	the	mucociliary	transport	
deficit	found	in	SPC	Tg+	animals.	The	inflammatory	cell	clearance	data	suggests	that	MCT	is	
elevated	following	mucolytic	treatment,	but	direct	observation	of	particle	movement	in	the	lung	
would	be	a	more	definitive	measure.	Going	beyond	the	ex	vivo	study	of	the	trachea	to	the	
examination	of	clearance	in	the	whole	lung	would	also	be	especially	useful.	Methods	such	as	
scintigraphy	[246]	would	potentially	allow	examination	of	mucolytic	activity	distally	in	vivo,	
providing	solid	evidence	of	clearance	in	the	area	of	lung	most	relevant	to	disease.		
The	removal	of	MUC5B	by	the	mucolytic	was	advantageous	in	terms	of	survival,	but	how	
precisely	it	helped	remains	unknown.	Additional	histological	studies	in	SPC	Tg+	could	
determine	if	trapped	bacteria	or	particulates	are	visible	in	the	distal	lung	of	untreated	animals.	
If	these	foreign	substances	disappear	following	mucolytic	treatment,	it	would	support	the	idea	
that	increased	clearance	is	beneficial	in	the	setting	of	MUC5B	overexpression.	Additionally,	
single	cell	RNA	sequencing	would	be	interesting	in	this	model	to	isolate	which	cells	are	being	
influenced	by	the	presence	of	excess	luminal	MUC5B	and	how	they	are	responding.	If	alveolar	
cells,	ciliary	cells,	or	bronchoalveolar	stem	cells	are	being	impacted	by	MUC5B,	then	changes	in	
their	transcriptional	profiles	would	help	assess	the	effects	of	excess	mucin.	As	an	added	benefit,	
single	cell	sequencing	would	answer	the	question	of	whether	AEC2	produce	MUC5B	in	the	
disease	state.		
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	 While	improved	clearance	is	hypothesized	to	be	the	main	effect	of	the	mucolytic	
compound,	the	possibility	that	the	observed	results	occurred	due	to	off-target	effects	must	be	
considered.	Thiol	compounds	have	known	antioxidant	properties	which	can	lessen	the	
cytotoxic	effect	of	bleomycin	[247].	In	fact,	the	ability	of	thiol	containing	antioxidant	
compounds,	such	as	N-acetylcysteine	(NAC)	to	completely	prevent	bleomycin	induced	fibrosis	
has	already	been	shown	[248].	Unfortunately,	a	large	human	trial	examining	NAC	treatment	in	
IPF	found	no	benefit	to	this	particular	therapy,	suggesting	that	antioxidant	activity	alone	is	
insufficient	to	slow	the	progression	of	fibrotic	disease	[249].	When	individuals	were	stratified	
by	rs35705950	genotype,	however,	NAC	therapy	appeared	helpful	specifically	for	those	with	
the	variant	allele	[250].	The	lack	of	effect	in	patients	with	the	wild	type	genotype	indicates	that	
NAC’s	antioxidant	properties	likely	do	not	improve	outcomes,	while	the	improvement	in	variant	
individuals	points	to	a	beneficial	thiol-mucus	interaction.	For	the	mice	in	this	experiment,	
assessment	of	glutathione	levels	in	both	mucolytic	and	vehicle	treated	lung	could	help	
determine	if	significant	differences	in	oxidant	status	contribute	to	better	outcomes	following	
mucolytic.		
	 Another	possible	mechanism	explaining	improved	outcomes	for	mucolytic	treated	
animals	lies	in	the	ability	of	the	drug	to	cause	clearance	of	inflammatory	cells.	While	the	week-
long	gap	between	bleomycin	exposure	and	mucolytic	treatment	should	minimize	direct	
interactions	between	the	two	agents,	inflammatory	cells	persist	in	the	lung	through	the	whole	
course	of	bleomycin	induced	disease.	Clearance	of	inflammatory	cells	due	to	mucolytic	
treatment	could	improve	survival	and	mitigate	fibrosis	by	removing	pro-inflammatory	signals	
that	increase	pulmonary	leakage	and	lymphocyte	reactivity.	The	poor	track	record	of	anti-
inflammatory	agents	in	treating	established	IPF	suggests	these	actions	likely	do	not	reduce	
fibrotic	progression.	Since	inflammation	is	crucial	in	the	bleomycin	exposed	mouse,	an	anti-
inflammatory	compound	can	show	success	at	reducing	murine	fibrosis	but	be	totally	ineffective	
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in	IPF,	again	demonstrating	the	limitations	of	this	model.	An	alternative	fibrotic	model,	perhaps	
one	based	on	asbestos	or	radiation,	will	be	necessary	to	begin	separating	anti-inflammatory	
from	anti-fibrotic	activity	of	the	mucolytic.		
	 Overall,	this	study	contributes	knowledge	regarding	the	relationship	between	Muc5b	
overexpression	and	predisposition	to	pulmonary	fibrosis.	Reducing	MUC5B	through	either	
genetic	or	pharmacologic	means	successfully	mitigated	fibrotic	development	while	increasing	
Muc5b	expression	proved	detrimental.	Potential	mechanisms	linking	damage	to	Muc5b	
expression	were	explored,	and	evidence	was	provided	in	support	of	both	cell	autonomous	and	
non-cell	autonomous	injury	(Figure	4.1).	However,	several	unanswered	questions	remain	
concerning	MUC5B	and	IPF.	Why	do	patients	who	develop	IPF	express	more	MUC5B	than	
controls,	regardless	of	genotype	at	rs35705950?	How	does	the	MUC5B	variant	lead	to	improved	
survival	while	also	contributing	to	increased	disease	susceptibility?	The	mouse	models	
described	here	may	assist	in	addressing	these	issues,	and	they	provide	a	valuable	foundation	
for	future	studies	into	treatment,	prevention,	and,	hopefully,	cure.			
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Proposed	model	of	MUC5B	induced	injury	
Figure	4.1:	MUC5B	plays	an	essential	role	in	the	healthy	lung	(top)	by	maintaining	mucociliary	
clearance.	In	the	setting	of	excess	MUC5B	expression,	such	as	that	associated	with	rs35705950,	
mucus	can	accumulate	(bottom).	This	luminal	accumulation	can	produce	non-cell	autonomous	
injury	through	decreased	mucociliary	transport	and	increased	particle	retention.	
Overexpression	may	also	exert	cell	autonomous	effects,	inducing	ER	stress	and	apoptosis	in	
secretory	cells.	Both	mechanisms	are	supported	by	findings	in	Chapter	III.		
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